GlassScriptPhysician profile
Justin Lapollo
NPI 1811124340
$4,405.21
in general payments reported to CMS, 2019-2025
19 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $1,156 · 2023: $735 · 2024: $1,068 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.82 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $645.78 | 2022-2023 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $569.32 | 2021-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $509.99 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $500.40 | 2022-2025 | Caplyta |
| Abbvie INC. | $418.06 | 2021-2025 | Vraylar |
| Alkermes, INC. | $327.23 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $298.56 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $233.96 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $186.28 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $135.57 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $121.18 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $109.77 | 2021-2024 | |
| Corium, LLC | $108.21 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $59.80 | 2023-2024 | Uzedy, Austedo Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.08 | 2025 | Rejoyn |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $47.22 | 2021-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $37.98 | 2024 | Cobenfy |
| Tris Pharma INC | $29.19 | 2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $17.63 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Lapollo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.